Previous 10 | Next 10 |
Clover Biopharmaceuticals said its contract development and manufacturing organization (CDMO) received a European Union Good Manufacturing Practice (EU GMP) certificate for producing the company's lead COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum). Clover created the ...
SHANGHAI, China, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd . (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, today announced that Clover’s contract development and manufacturing orga...
-- 5-fold higher neutralizing antibodies against dominant Omicron BA.5 in participants who received SCB-2019 (CpG 1018/Alum) as a heterologous third dose after two doses of inactivated vaccine compared to a third dose of inactivated vaccine -- -- New Phase 3 data underscores the p...
Dynavax Announces First Participant Dosed in a Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine PR Newswire EMERYVILLE, Calif. , Sept. 12, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharma...
Summary Bearish sentiment weighed heavily on the biotech industry and Bavarian Nordic A/S. There is reason for optimism given the current opportunities offered by Monkeypox, Ebola and Covid-19. The company is preparing for a new era of high-risk tropical infections and coronav...
Dynavax to Present at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire EMERYVILLE, Calif. , Sept. 8, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing ...
Clover Biopharmaceuticals said its COVID-19 vaccine SCB-2019 (CpG 1018/Alum) elicited superior levels of neutralizing antibodies against the original strain and Omicron subvariants BA.1 and BA.2 when given as a heterologous third dose in people who previously received two doses...
-- U p to 12-fold higher neutralizing antibody titers observed in participants who received SCB-2019 (CpG 1018/Alum) as a heterologous third dose after two doses of inactivated vaccine compared to a third dose of inactivated vaccine -- - - Superior immune...
Clover Biopharmaceuticals said its COVID-19 vaccine SCB-2019 (CpG 1018/Alum) elicited a robust immune response to Omicron BA.5 subvariant in a phase 2/3 trial, building upon previous results for neutralization against Omicron BA.2. The Chinese company added that in results come ...
Clover Biopharmaceuticals said its COVID-19 vaccine SCB-2019 met the main goal of a global phase 2/3 trial. The Chinese company added that in the trial — which enrolled 1,278 people — SCB-2019 (CpG 1018/Alum) elicited almost 2-fold higher neutralizing a...
News, Short Squeeze, Breakout and More Instantly...
Dynavax Technologies Corporation Company Name:
DVAX Stock Symbol:
NASDAQ Market:
Dynavax Technologies Corporation Website:
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 PR Newswire EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company dev...
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program PR Newswire EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing inn...
2024-06-21 02:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...